Close Menu
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

How Termina Selected and Ranked the 2026 Seed 100, Seed 40 Lists

May 18, 2026

OpenAI and Anthropic Are Kicking Off a Cybersecurity Frenzy

May 18, 2026

The Ex Google Executive Wants to Get People Off Their Screens.

May 18, 2026
Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
Home » FDA approves HIV prevention drug taken as twice-yearly injection
Health

FDA approves HIV prevention drug taken as twice-yearly injection

IQ TIMES MEDIABy IQ TIMES MEDIAJune 19, 2025No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

Daniel O’Day, Gilead’s chairman and chief executive officer, called the approval a “milestone moment in the decades-long fight against HIV.”

“Yeztugo will help us prevent HIV on a scale never seen before. We now have a way to end the HIV epidemic once and for all,” O’Day said in a news release.

According to the Centers for Disease Control and Prevention, there were 31,800 estimated new HIV infections in the United States in 2022, the most recent year with available data.

While the drug’s approval meets an existing need, the Trump administration’s funding decisions have rolled back progress for a vaccine.

Last month, the administration moved to end funding for a broad swath of HIV vaccine research, saying current approaches are enough to counter the virus.

Dr. Barton Ford Haynes, the director of the Duke Human Vaccine Institute, recently told CBS News lenacapavir is a “wonderful development for the field,” but said there was still a need for a vaccine.

“For HIV vaccine design and development, we’ve begun to see light at the end of the tunnel after many years of research,” Dennis Burton, an immunology professor at Scripps Research, previously told CBS News. “This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials.”

Burton warned that their HIV vaccine research could not simply be turned back on, even if a future administration decided to change course on HIV funding. He said ongoing experiments would be shuttered, and researchers assembled to study the issue would be forced to refocus their careers on other topics.

“This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research,” Burton said.

Teen questioned after family’s quadruple murder

Iranians evacuate capital Tehran, some say the regime is frightened

Parents, brother of slain Minnesota lawmaker Melissa Hortman speak about her death



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
IQ TIMES MEDIA
  • Website

Related Posts

What an expert on the gut microbiome eats in a day

March 26, 2026

Wegovy maker Novo sharpens consumer focus with board role for Mars CEO

March 26, 2026

CDC report finds US smoking rate continues to plummet as vape use rises

March 26, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Hungary and Ukraine to hold talks on ethnic Hungarian minority rights

May 18, 2026

Trial to start for ex-assistant principal accused of ignoring warnings that student had gun

May 18, 2026

Michigan student will be 1st woman to represent US in world welding competition

May 17, 2026

Nashville HBCU Fisk University Launches $900M Campus Transformation

May 15, 2026
Education

Hungary and Ukraine to hold talks on ethnic Hungarian minority rights

By IQ TIMES MEDIAMay 18, 20260

BUDAPEST, Hungary (AP) — Hungary and Ukraine will begin high-level consultations on the rights of…

Trial to start for ex-assistant principal accused of ignoring warnings that student had gun

May 18, 2026

Michigan student will be 1st woman to represent US in world welding competition

May 17, 2026

Nashville HBCU Fisk University Launches $900M Campus Transformation

May 15, 2026
IQ Times Media – Smart News for a Smarter You
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 iqtimes. Designed by iqtimes.

Type above and press Enter to search. Press Esc to cancel.